Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.58 -0.01 (-0.01%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.12 PB Ratio: 1.76 GF Score: 85/100

Jazz Pharmaceuticals PLC at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 01:00PM GMT
Release Date Price: $115.29 (-7.85%)
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Thank you for your time this morning. I'll just say, I will make forward-looking statements. You'll see our risk factors on our SEC filings, and I may refer to adjusted GAAP numbers, and we always provide a reconciliation on our website.

So it's been a productive start to 2020 for Jazz. In addition to just announcing our 2019 results and our 2020 guidance, we've had a product approved, submitted an NDA and had another NDA accepted for filing with priority review. So that puts us well on track to achieve our objective of launching 4 new products in the next 18 months or so. So a real catalyst-rich time for the company, and we'll look forward to continuing to demonstrate through our regulatory progress, our development progress, our commercial progress, how we're diversifying the top line for sustainable growth.

Coronavirus, my favorite topic. I'll just say no direct impact to us thus far. When we think about impact to the business, we start with impact to patients, making sure we can supply product on a reliable

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot